Efficacy of low dose peginterferon alpha-2b with ribavirin on chronic hepatitis C

Table 1 Demographic, clinical, biochemical and molecular profiles of patients (mean ± SD, n = 28)

Demographic profile
M/F	25:3
Age (yr)	47.5 ± 13.2
Body weight (kg)	60.6 ± 9.18
Clinical profile
Chronic hepatitis C (n)	15
Compensated cirrhosis (n)	13
ALT ( > 40 IU/L)	18
ALT (< 40 IU/L)	10
Molecular profile
Genotype 3 (n)	21
Genotype 2 (n)	5
Genotype 1 (n)	2
Follow-up (mo)	18.1 ± 6.7

Table 2 Response of therapy with respect to dose and genotype

Patients(n = 28)	Response topeginterferon alpha 2bDose 50 mcg (n = 14)		Response topeginterferon alpha 2bDose 80 mcg (n = 12)1
	Yes	No	Yes	No
Genotype 1 (n = 2)	-	1	1	-
Genotype 2 (n = 5)	3	-	2	-
Genotype 3 (n = 21)	8	2	8	1

¹Two patients in group 2 did not complete therapy.